Proqr Therapeutics NV Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
Boer Daniel Anton De, Chief Executive Officer and a Director of ProQR Therapeutics N.V., purchased 200,000 shares of common stock on July 31, 2026 for $1.77 per share.
NASDAQ
Bart Filius, a Director of ProQR Therapeutics N.V., purchased 150,000 shares of common stock on July 17, 2026 for $1.72 per share.
NASDAQ
Boer Daniel Anton De, Chief Executive Officer and a Director of ProQR Therapeutics N.V., purchased 150,000 shares of common stock on July 9, 2026 for $1.74 per share.
NASDAQ
ProQR Therapeutics N.V. reports a significant share purchase by its CEO and Director, Daniel Anton de Boer.
NASDAQ
ProQR Therapeutics N.V. files an amended Form 4 to correct the number of share options reported for Director Gylvin Lykke Hinsch.
NASDAQ
ProQR Therapeutics N.V. reports a significant share acquisition by Director Bart Filius.
NASDAQ
ProQR Therapeutics N.V. reports a Form 4 filing detailing a director's acquisition of stock options.